Tjänster vi kan rekommendera till dig som vill bevaka, analysera eller handla aktier i Orphazyme (DK).
Redeye provides a follow-up note after listening to the presentation of the top-line results with arimoclomol in ALS.
Redeye provides a first comment on the disappointing top-line results in ALS.
Redeye provides a follow-up note to the top-line results in sporadic Inclusion Body Myositis (sIBM) and after having spoken to the managemen...
Redeye provides the first comment to the top-line results presented with arimoclomol in sIBM.
Redeye gives its reflections on Orphazyme’s financials for the full year 2020 and the corresponding conference call.
Redeye provides a first reflection on the appointment of Christophe Bourdon as Chief Executive Officer.
Redeye reiterates its probability rate for arimoclomol in NPC.
Redeye revisits the Orphazyme case in light of exceptional news flow in the first half of 2021.
Redeye gives a first impression, following the news of CEO Stratton’s resignation.
Redeye sees positive that arimoclomol in NPC now enters the filing stage in Europe as well.
Redeye updates its estimates for 2020 following corporate communication.
Redeye recognizes the first day of trading in the US, with a global offering carried out in conjunction.
Redeye gives a view on Friday’s news, where Orphazyme gave an update on the global offering process.
Redeye gives a first comment on the news that Orphazyme commences a global offering.
Redeye acknowledges another critical step towards approval for arimoclomol, as the FDA has accepted, with priority review, Orphazyme’s New D...
Redeye is encouraged by the progress towards a potential dual listing in the U.
Redeye provides a second note, following the conference call in conjunction with the H1’20 report.
Redeye gives its first reflections on Orphazyme’s H1’20 report published this morning.
Redeye acknowledges that Orphazyme has built further value in its pipeline during the latest days, following increasing commitments in PD, a...
Earlier today, we learned that Orphazyme had submitted a draft registration statement for a potential public offering in the United States.
Redeye reckons phase II results far from perfect, possibly due to the small sample size and an overall tricky population group.
Redeye acknowledges a significant milestone for Orphazyme, following the initiation of a rolling NDA submission to the FDA.
Redeye gives a brief view of the news that Orphazyme has received its third US Fast Track Designation with its lead compound, arimoclomol.
Last week, Orphazyme announced the full-year results for 2019 and published its annual report for 2019.
The case for Orphazyme continues to strengthen as arimoclomol’s US early access program reinforces a raft of positive data and regulatory pr...
Orphazyme has reported long-awaited results from the open-label phase 2/3 extension study (OLE).
During November and December, Orphazyme has received both breakthrough therapy designation and Fast Track designation by FDA in two separate...
Last week, Orphazyme announced the results for their first half a year.
We here provide a short note to the news that Orphazyme prepares for filing in the US with arimoclomol in Niemann-Pick disease Type C (NPC).
Earlier today, Orphazyme announced that they have completed enrollment in the phase III program with arimoclomol in Amyotrophic Lateral Scle...
Earlier today, Orphazyme announced that they have appointed Kim Stratton as the new CEO for the company, succeeding Anders Hinsby.
Orphazyme today announced, based on feedback from the European Medical Agency (EMA), that they are preparing for filing with arimoclomol in ...
Orphazyme today announced that the ongoing phase II/III trial in patients with sporadic Inclusion Body Myositis (sIBM) is fully enrolled.
Arimoclomol in the NPC indication will drive the story in the near-term but Orphazyme has a broad pipeline with multiple potential value dri...
Additional details from the 12-month NPC trial gives a better understanding of arimoclomol in NPC, but there's still uncertainty around the ...
Orphazyme today reported the detailed follow-up data from their NPC Phase II/III clinical trial, from which preliminary top-line data was re...
Anders Hinsby, vd på Orphazyme, ger oss en kort beskrivning av bolaget och vad som ligger i pipeline.
Mallinckrodt has announced that their VTS-270 project, a competitor to Orphazyme's arimoclomol for the treatment of NPC, failed to show stat...
Top-line data with arimoclomol showed a promising efficacy at 12 months.
Orphazyme has reported top-line results for the NPC Phase II/III trial, showing a treatment benefit of arimoclomol over placebo at 12 months...
Vi har inte hittat några nyheter än.
|Börsvärde||1 004 MDKK|
Vill du få en automatisk notis när det kommer en nyhet om Orphazyme (DK)? Då rekommenderar vi att du laddar ner vår app idag!